Wasman Jane

Wasman Jane is listed in filings as Director at Rigel Pharmaceuticals, Inc.. This profile follows SEC Form 4 activity through May 19, 2026, including purchase activity. Recent filings connect the profile to Rigel Pharmaceuticals, Inc. (RIGL) and SELLAS Life Sciences Group, Inc. (SLS). The current snapshot covers public activity from Jan 14, 2025 to May 19, 2026. Reported amounts are shown as $33.8K to $17.6K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.